Gilead Sciences
Gilead Partners with Tubulis to Revitalize ADC Pipeline
Gilead Sciences, Tubulis, Antibody-Drug Conjugates (ADCs), Cancer Treatment, Biotechnology Partnership
Gilead Sciences Acquires Investigational HIV Vaccine Assets from AELIX Therapeutics
Gilead Sciences, AELIX Therapeutics, HIV vaccine, HTI immunogen, IrsiCaixa, HIVACAT program
Gilead Sciences Announces Layoffs at California HQ and Closure of Seattle Office
Gilead Sciences, layoffs, California HQ, Seattle office closure, biopharma, workforce reduction
Gilead Sciences and Kite Pharma Announce Layoffs, Closure of Seattle and Philadelphia Offices
Gilead Sciences, Kite Pharma, layoffs, office closures, Seattle, Philadelphia, biotech industry, restructuring
Gilead Sciences Surpasses Q3 Earnings and Sales Forecasts, Boosts Annual Outlook
Gilead Sciences, Q3 earnings, HIV drug sales, annual guidance, Biktarvy, Veklury, lenacapavir, HIV prevention
Gilead Withdraws Trodelvy for Bladder Cancer in US After Confirmatory Trial Failure
Gilead Sciences, Trodelvy, bladder cancer, urothelial carcinoma, FDA, accelerated approval, drug withdrawal
Gilead Expands HIV Drug Access, Yet Faces Criticism Over Exclusion of Middle-Income Countries
Gilead Sciences, HIV drug access, Lenacapavir, Generic licensing agreements, Middle-income countries exclusion, HIV prevention, Pre-exposure prophylaxis (PrEP)
Gilead Expands Access to Long-Acting HIV PrEP with Licensing Deals for Generic Lenacapavir
Gilead Sciences, lenacapavir, HIV PrEP, generic licensing, long-acting HIV prevention, global health access
Gilead’s Kite Unit Exits China CAR-T Joint Venture with Fosun
Gilead Sciences, Kite Pharma, Fosun Pharma, CAR-T cell therapy, joint venture, China, Yescarta
Gilead Partners with Yuhan for $81M HIV Drug Ingredient Supply Deal
Gilead Sciences, Yuhan, HIV drug ingredients, $81M deal, pharmaceutical partnership